36 results about "Circumsporozoite protein" patented technology

A composition for preventing malaria infection including a protease inhibitor. A pharmaceutical composition for preventing malaria infection including a protease inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by inhibiting circumsporozoite protein processing or by inhibiting a protease of a sporozoite. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing.

Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.

The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.

Methods are provided for reducing the activity or function of an inflammatory cell by contacting a cell with, or administering to a subject in need thereof, an effective amount of a circumsporozoite protein or homolog thereof, or a fragment thereof. Methods of treating an inflammatory disease, or an autoimmune disease or for inducing tolerance are also disclosed as are pharmaceutical compositions comprising a therapeutically effective amount of a circumsporozoite protein or homolog thereof, or a fragment thereof and a pharmaceutically acceptable carrier.

The invention discloses a hepatic targeting peptide and angiogenesis inhibitor fusion protein as well as a preparation method and an application thereof. According to the invention, 19 amino acids, which can be specifically combined with an acceptor on the hepatocyte surface (namely heparin sulfate proteoglycan), in a circumsporozoite protein (CSP) N-terminal conserved block I (CSPI-plus) are adopted, and are fused on the amino or carboxyl terminal of the angiogenesis inhibitor by a genetic engineering process to prepare the hepatic targeting peptide and angiogenesis inhibitor fusion protein. The fusion protein can specifically target the liver to inhibit the neovascularization, improve the local concentration of focus part, reduce the dosage of a whole body and reduce the toxic and side effects.

There is provided peptide and mimetic inhibitors for the binding of a circumsporozoite polypeptide to receptors of hepatocytes from malaria-susceptible mammals. Also contemplated is a method of inhibiting the binding of a malaria sporozoites to hepatocytes susceptible to sporozoite invasion. A peptide of Region II+ of the circumsporozoite protein is also provided, as is a method of targeting the delivery of substances to hepatocytes.

The invention relates to a geographically-specific Plasmodium vivax molecule marker, and its application in strain tracing. The molecule marker includes a Plasmodium vivax circumsporozoite protein center replication region reflecting mosquito infection differences of different media, a height polymorphism microsatellite reflecting mutation, migration and genetic drift, and a drug resistance related gene mutation reflecting the population positivity selection of drug control. Results show that each of a Plasmodium vivax circumsporozoite protein center replication region sequence, dihydrofolate reductase SNP, dihydrobiopterin synthetase SNP, a neutral microsatellite and the like has a geographic specificity, and can be used as a classification index in tracing detection.

The present invention relates to processes for purifying high-quality recombinant Plasmodium falciparum circumsporozoite protein at high yields.

The invention discloses a new application of plasmodium circumsporozoite protein CSP for preparing medicaments for anti-tumor multiplication and migration. The invention successfully constructs a recombinant expression carrier pFLAG-CMV8-CSP of the CSP and transfects the recombinant expression carrier into a human liver cancer cell strain HepG2 and a colorectal cancer cell strain SW480 in a manner of liposome transfection. The research result shows that the CSP is mainly expressed in the cytoplasm of HepG2 cells, can restrain TNF-Alpha and LPS, stimulate the HepG2 cells and SW480 cells to activate NF-Kappa B and restrain the multiplication of the SW480 cells, and is further developed into a novel protein medicament for the anti-tumor multiplication and migration hopefully; and the recombinant expression carrier containing the gene of the CSP is hopefully further developed into the novel protein medicament for the anti-tumor multiplication and migration, therefore, the invention has favorable clinical application prospect.

A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition.

The invention is an DNA vaccine and method of use thereof for modulating the immune response against the circumsporozoite protein (CSP) of malaria parasites, using the CR2 binding motifs of C3d, especially p28.

Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes in the polyepitope constructs are from regions of the Plasmodium falciparum circumsporozoite protein (CSP) known to contain CD4 and CD8 T cell epitopes, and include both epitopes from highly variable and highly conserved regions of CSP.

The invention discloses novel application of the peptide fragment CSP I-plus of circumsporozoite protein CSP I-plus of plasmodium in treating plasmodium infection. Researches discover that the circumsporozoite protein CSP plays an important role in adhesion and hepatic cell invasion of plasmodium sporozoite, and the key point of malaria infection is that sporozoite of plasmodium invades liver cells, so that malaria infection can be prevented by stopping invasion of sporozoite. CSP I-plus is an important functional domain of CSP, can be specifically combined with a liver cell surface molecule, namely heparan sulfate proteoglycan (HSPG), and can stop combination of CSP and the liver cells. Therefore, the CSP I-plus is expected to be developed into a novel micro-molecule polypeptide medicine for treating plasmodium falciparum infection by stopping adhesion and liver cell invasion of CSP mediated plasmodium sporozoite, and the recombinant expression plasmid containing CSP I-plus coding genes is expected to be further developed into a novel anti-malarial genetic medicine, so that the circumsporozoite protein polypeptide CSP I-plus has an excellent clinical application prospect.

The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.

The invention belongs to the biomedicine field, relating to a malaria infrared stage DNA vaccine and a preparing method thereof. The vaccine is obtained by connecting the coding gene of N end segment (amino acid sequence shown as SEQ ID No. 1) of heat shock protein (gp96) with the coding gene of the circumsporozoite protein (amino acid sequence shown as SEQ ID No. 3) in series and inserting into eukaryotic expression plasmid. The preparing method of the invention comprises three steps: the construction of recombinant plasmid pMD19 simple T/CSP, the construction of recombinant plasmid pFLAG-CMV8-gp96NTD, and the construction of recombinant plasmid pFLAG-CMV8-gp96NTD/CSP. The vaccine is able to simultaneously induce anti-CSP antibody generation and CD8+T cell reaction, thereby obtaining the plasmodium-specified complete protective immunization, and has great application prospect in preventing malaria inflection.

Mutated and/or truncated malarial circumsporozoite proteins (CSP) and associated nucleic acids that are more stable and highly expressed in mammalian cells are described. The mutated and/or truncated CSP and associated nucleic acids can be expressed to produce malaria vaccine antigens.

The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.